TY - JOUR
T1 - Mitoxantrone, methotrexate, and 5‐fluorouracil combination chemotherapy as first‐line treatment in stage IV breast cancer
AU - Bezwoda, Werner R.
AU - Hesdorffer, Charles S.
PY - 1986/1/15
Y1 - 1986/1/15
N2 - Fifty patients with Stage IV breast cancer were entered into a prospective Phase II trial of combination chemotherapy that consisted of mitoxantrone (10 mg/m2), methotrexate (40 mg/m2), and 5‐fluorouracil (600 mg/m2) given in a 3‐weekly schedule. Objective response to treatment was seen in 18 of 48 assessable patients (38%). Responses were seen predominantly in the lung and pleura and the node and soft tissue sites of disease. The median duration of response was 7 months. Toxicity from treatment consisted predominantly of reversible leukopenia. Other toxicities such as nausea and alopecia occurred in less than one half of the patients in the study group. The combination was well‐tolerated, and appears to be moderately effective.
AB - Fifty patients with Stage IV breast cancer were entered into a prospective Phase II trial of combination chemotherapy that consisted of mitoxantrone (10 mg/m2), methotrexate (40 mg/m2), and 5‐fluorouracil (600 mg/m2) given in a 3‐weekly schedule. Objective response to treatment was seen in 18 of 48 assessable patients (38%). Responses were seen predominantly in the lung and pleura and the node and soft tissue sites of disease. The median duration of response was 7 months. Toxicity from treatment consisted predominantly of reversible leukopenia. Other toxicities such as nausea and alopecia occurred in less than one half of the patients in the study group. The combination was well‐tolerated, and appears to be moderately effective.
UR - http://www.scopus.com/inward/record.url?scp=0022629853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022629853&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19860115)57:2<218::AID-CNCR2820570205>3.0.CO;2-J
DO - 10.1002/1097-0142(19860115)57:2<218::AID-CNCR2820570205>3.0.CO;2-J
M3 - Article
C2 - 3753656
AN - SCOPUS:0022629853
SN - 0008-543X
VL - 57
SP - 218
EP - 221
JO - Cancer
JF - Cancer
IS - 2
ER -